

# **What's New With Your Maryland State Lab.**

**Richard Oatis  
Supervisor, Mycobacteriology**

**State of Maryland  
Department of Health and Mental Hygiene  
Labs Administration  
1770 Ashland Ave  
Baltimore, MD 21205  
(443)681-3944  
[richard.oatis@maryland.gov](mailto:richard.oatis@maryland.gov)**

# **In case you plan on falling asleep...**

- **Lab move to the new facility.**
- **Specimen quality assurance.**
- **GeneXpert testing for smear-negative specimens.**
- **Quantiferon testing: what we do now and what's next.**

# Contact info:

- **Lab results (Val): (443)681-3942**
- **Weird questions (Rich): (443)681-3944**
- **Fax: (443)681-4506**
- **Website:**  
**[http://dhmh.maryland.gov/laboratories/Pages/Tuberculosis-\(TB\)-Laboratory.aspx](http://dhmh.maryland.gov/laboratories/Pages/Tuberculosis-(TB)-Laboratory.aspx)**

# The new building:



# Main lobby:



# BSL-2 space:



# BSL-3 space:



# Today:





# Our view:



# **Growing pains...**

- **Move begins 04/16/15, but small cracks in HEPA filter housing prevent work at 1770 until 04/26/15.**
- **Drain pipe leak in penthouse shuts down main processing lab in September 2015. Repairs continue...**

# **Our new BSL-3**

- **Separate suite of labs isolated from the rest of the lab space.**
- **Designed with additional features to enhance biological containment.**
- **Restricted access – a code is required to get in.**
- **Employees working in BSL-3 must sign in/out and notify security upon entrance/exit.**

# BSL-3 PPE



# Powered Air Purifying Respirator (PAPR):





# Quality specimens

- **Our results can only be as good as the specimen we receive.**
- **We hope to assist all TB cases managers and physicians in providing the best possible TB specimens.**

# **Sputum specimens**

- **First morning specimens are often best.**
- **5 mL is the optimum volume.**
- **Watery specimens may not yield good results!**



# **Other specimen collection considerations:**

- **Check that tube is closed tightly and properly as much as possible!**
- **Check that biohazard “ziplock” bag is sealed properly.**
- **Refrigerate specimens as much as possible during storage/transport.**
- **Submit to lab ASAP – do not batch!**

**Our goal for time to specimen receipt in lab is 24 hours!**

- **Expedite lab testing.**
- **Disallow for the growth of contaminating organisms.**

# Contaminated cultures:

---

## TB Clinical

### Microscopy Report

Fluorochrome -                      AFB Not Found

Performed by: M. Plehn

Date: 1/11/16

### Final Culture Report

Contaminated. Please submit another sample.

Performed by: A. Rivera

Date: 1/28/16

# Current turnaround times:

CY2015	CY2014	Description of turnaround times (TAT) for initial diagnostic specimens
		1. Promote rapid delivery of specimens. (TAT goal: Specimens should be received in the laboratory within 24 hours of specimen collection.) Report the percent of specimens received within 1, 2, and 3 calendar days.
14	28	% of specimens received within 1 calendar day.
39	54	% of specimens received within 2 calendar days.
59	69	% of specimens received within 3 calendar days.

# **How can we work together to solve this?**

- **Identify changes to practices or workflow to expedite specimen submission.**
- **Notify the lab of any ways we may be to assist – would adjustments to courier schedule help?**

# GeneXpert

- **Nucleic acid amplification (NAA) assay for direct detection of *M. tb* complex.**
- **Only can be performed on respiratory (sputum, bronch wash, etc.) and tissue specimens.**
- **Also detects mutations associate with Rifampin resistance.**

# **GeneXpert – when should it be done?**

- **All smear-positive specimens with no recent history of AFB + culture.**
- **Specimen should be within 3 days of start of treatment.**
- **Performed within 7 days of being processed in lab.**
- **Can be performed on smear-negative specimens upon phone request.**

# **CDC recommends:**

- **“NAA testing should be performed on at least one respiratory specimen from each patient with signs and symptoms of pulmonary TB for whom a diagnosis of TB is being considered but has not yet been established, and for whom the test result would alter case management or TB control activities.”**
- **<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm>**



## **At our lab:**

- **316 patients tested with GX in 2015, up from 223 in 2014.**
- **Of the 316 tested, 142 were requested on smear-negative specimens (45%).**
- **Of these 142 requested, only 4 were GeneXpert positive (3%).**

# Concerns of these results:

- **Money/lab time spent.**
- **Negative results can be misleading –  
GX should not be used to rule out TB!**

# **Negative GeneXpert result:**

- **In 2015, there were 5 patients with negative GeneXpert results but positive cultures.**
- **Another 5 cases were only positive upon testing a second specimen.**
- **These concerns increase with smear-negative specimens – too few TB bacilli to detect!**

# **What we can do as a result:**

- **All GeneXpert results should be interpreted in light of patient history/clinical presentation.**
- **Be mindful of specimen quality.**
- **Call the lab and request additional tests be run if there are concerns with negative results.**

# **GeneXpert to remove patients from respiratory isolation:**

- **First announced February 2015.**
- **“One or two” negative GeneXpert results is sufficient for removing TB suspects from isolation.**
- **NOT intended for patients with confirmed active TB - not a good test of cure.**
- **<http://ir.cepheid.com/releasedetail.cfm?releaseid=896300>**

# Take home messages:

- **All TB suspects should have a GeneXpert requested.**
- **GeneXpert should not be used to “rule out” TB – culture results still important!**
- **Specimen quality, patient history, and clinical presentation all need to be considered when interpreting GeneXpert results.**

# Quantiferon

- **An interferon-gamma release assay whereby whole blood is exposed to proteins specific to *M. tb.* complex (but not BCG) to test for latent TB infection.**
- **The test requires three specialized collection tubes: a blank (Nil) tube, the test (Antigen) tube, and a positive (Mitogen) tube.**
- **Only known to cross-react with three fairly uncommon Mycobacterial infections: *M. kansasii*, *M. marinum*, *M. szulgai*.**

# Quantiferon: how do we interpret results?

Nil [IU/mL]	TB Antigen minus Nil [IU/mL]	Mitogen minus Nil [IU/mL] <sup>1</sup>	QuantiFERON <sup>®</sup> -TB [IU/mL]	Report/Interpretation
≤ 8.0	< 0.35	≥ 0.5	<b>Negative</b>	<i>M. tuberculosis</i> infection NOT likely
	≥ 0.35 and < 25% of Nil value	≥ 0.5		
	≥ 0.35 and ≥ 25% of Nil value	Any	<b>Positive<sup>2</sup></b>	<i>M. tuberculosis</i> infection likely
	< 0.35	< 0.5	<b>Indeterminate<sup>3</sup></b>	Results are indeterminate for TB Antigen responsiveness
≥ 0.35 and < 25% of Nil value	< 0.5			
> 8.0 <sup>4</sup>	Any	Any		



# **The controversy:**

- **No equivocal zone around cut point lends to “flip flopping” upon repeat testing.**
- **Some research suggests a higher cutoff point (.70) may yield results with better correlation to other testing methods.**

# **Why must our lab use 0.35?**

- **FDA approved the test with this cut point.**
- **Must interpret the test as described in package insert by Federal regulation.**

# Why isn't the cutoff being changed?

- **No gold standard for latent TB infection.**
- **Balancing sensitivity (rate of false negatives) vs. specificity (rate of false positives).**
- **\$\$\$\$**

# **What do the numbers mean?**

- **Amount of CD4 cells in specimen.**
- **How well blood tubes were shaken during collection.**
- **How long blood tubes were incubated.**
- **Variations in preparation of reagents in lab.**
- **Room temperature of lab.**
- **Time between blood collection and testing.**

# **What this means for you:**

- **Interpretation on lab report (positive, negative, indeterminate) is more important than the numbers.**
- **Still must be interpreted in light of patient history.**

# **How does the lab assure the quality of QFT results?**

- **Positive and negative controls run daily as well as kit standards.**
- **All positive results repeated to demonstrate precision.**
- **Discordant results repeated until an consensus reached.**
- **Testing can be repeated on same specimen up to a week from receipt if there are concerns.**

# **What's next for QFT?**

- **Quantiferon-TB Gold Plus.**
- **May receive FDA approval some time this year.**
- **Already seeing use overseas.**

# **The good:**

- **Designed to stimulate CD8 as well as CD4 blood cells.**
- **May better capture recent exposures, active TB disease, HIV + patients, and young children.**
- **Mostly no change to specimen collection, processing, and testing procedure.**



# **The bad: 4 tubes instead of 3!**

- **2 separate antigen tubes: one targeting CD4 cells, one targeting CD8 cells.**
- **More time to collect, more discomfort for patients.**
- **More time to test in lab.**

# **The ugly: \$\$\$\$!**

- **One would expect tubes to cost more per test since 1 additional tube required.**
- **Less tests will fit on each ELISA plate, which may add cost.**
- **But what about additional savings?**

# Current QFT plate layout:

	1	2	3	4	5	6	7	8	9	10	11	12
A	1N	1A	1M	S1	S1	9N	9A	9M	17N	17A	17M	25N
B	2N	2A	2M	S2	S2	10N	10A	10M	18N	18A	18M	25A
C	3N	3A	3M	S3	S3	11N	11A	11M	19N	19A	19M	25M
D	4N	4A	4M	S4	S4	12N	12A	12M	20N	20A	20M	26N
E	5N	5A	5M	S5	S5	13N	13A	13M	21N	21A	21M	26A
F	6N	6A	6M	S6	S6	14N	14A	14M	22N	22A	22M	26M
G	7N	7A	7M	S7	S7	15N	15A	15M	23N	23A	23M	
H	8N	8A	8M	S8	S8	16N	16A	16M	24N	24A	24M	

# Possible QFT-Plus plate layout:

	1	2	3	4	5	6	7	8	9	10	11	12
A	1 N	3 N	5 N	7 N	9 N	S1	S1	13 N	15 N	17 N	19 N	21 N
B	1 TB1	3 TB1	5 TB1	7 TB1	9 TB1	S2	S2	13 TB1	15 TB1	17 TB1	19 TB1	21 TB1
C	1 TB2	3 TB2	5 TB2	7 TB2	9 TB2	S3	S3	13 TB2	15 TB2	17 TB2	19 TB2	21 TB2
D	1 M	3 M	5 M	7 M	9 M	S4	S4	13 M	15 M	17 M	19 M	21 M
E	2 N	4 N	6 N	8 N	10 N	11 N	12 N	14 N	16 N	18 N	20 N	22 N
F	2 TB2	4 TB1	6 TB1	8 TB1	10 TB1	11 TB1	12 TB1	14 TB1	16 TB1	18 TB1	20 TB1	22 TB1
G	2 TB2	4 TB2	6 TB2	8 TB2	10 TB2	11 TB2	12 TB2	14 TB2	16 TB2	18 TB2	20 TB2	22 TB2
H	2 M	4 M	6 M	8 M	10 M	11 M	12 M	14 M	16 M	18 M	20 M	22 M

# **What will it take to get us there?**

- **FDA approval...???**
- **Training...should be minimal.**
- **Lab validation of assay – may present challenges.**
- **Updating our LIMS to accommodate extra tube result.**

**Questions?**